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Abstract We investigated the effects of proadrenomedullin N-
terminal 20 peptide (PAMP) and adrenomedullin (AM) on the 
growth of human neuroblastoma TGW cells. Both PAMP and 
AM inhibited growth and DNA synthesis in neuroblastoma cells. 
Calcitonin gene-related peptide (CGRP)8 37, an antagonist to 
CGRP, abolished the inhibitory effect of AM on growth and 
DNA synthesis of neuroblastoma cells but did not affect that of 
PAMP. AM22 52) an antagonist to AM, also reversed the effect 
of AM. On the other hand, pertussis toxin (PTX) and 00-
conotoxin GIVA blocked the effect of P A M P alone. Thus, 
P A M P inhibits the growth of neuroblastoma cells by inhibiting 
N-type Ca 2 + channels through PTX-sensitive G protein-coupled 
receptors, which is different mechanism of AM-induced inhibi-
tion of the cell growth. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Proadrenomedullin N-terminal 20 peptide (PAMP) [1] is a 
novel gene-related peptide of adrenomedullin (AM) [2], which 
is recently identified vasodilator peptide from human pheo-
chromocytoma. Both P A M P and A M are hypotensive pep-
tides generated from post-transcriptional enzymatic process-
ing of the 185-amino acid prepro-AM molecule [1-3]. 
However, they exhibit the vasodilator effect through different 
ways. A M exhibited the direct vasodilator effect associated 
with increased cyclic A M P in vascular smooth muscle cells 
(VSMC) [4] whereas P A M P dilates vasculature through the 
sympathetic nerve suppression [5,6]. 
The vasodilator effect with A M is blocked by the antagonist 
of C G R P , CGRP 8 _ 3 7 , suggesting that the effect of A M is 
mediated through CGRP-related receptor [4]. However, in-
creased cyclic A M P with A M is not inhibited by CGRP 8-37 
in vascular endothelial cells [7] so the A M receptors in endo-
thelial cells are different from VSMC. Study using 1 2 5I-AM 
indicates that A M receptors exist in plenty of tissues such as 
lung and heart and that there are several kinds of A M recep-
tors [8]. Recently, one of A M receptors that contains 7 trans-
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membrane domains have been cloned and it is the orphan 
receptor that has been originally isolated from rat lung [9]. 
This receptor does not respond to C G R P and exhibits A M -
specific elevation of cyclic A M P . On the other hand, P A M P 
has no homology of amino acid sequence to A M or C G R P 
and its vasodilator effect through the sympathetic suppression 
is not inhibited by CGRP8_37 [5,6]. Pertussis toxin (PTX)-
sensitive G protein may inhibit N-type Ca 2 + channels and 
mediate the inhibition of norepinephrine release with P A M P 
[10,11]. Moreover, the recent report indicates that specific 
binding sites for P A M P are widely distributed in many organs 
such as brain, lung, aorta, kidney, adrenal glands [12] so 
P A M P may show the other effect than the sympathetic sup-
pression. 
In addition to vasodilator effect, A M has been reported to 
modify cell growth. For example, A M suppresses the growth 
of rat mesangial cells through enhanced cyclic A M P pathway 
[13], whereas it stimulates growth in Swiss 3T3 cells, which is 
also mediated by elevation of cyclic A M P [14]. However, there 
has been no data concerning the effect of P A M P on cell 
growth. Thus, we investigated the effect of P A M P as well as 
A M on the growth of human neuroblastoma T G W cells [15] 
because P A M P acts on neural cells [5,6,10,11] and because 
neuroblastoma cells have a receptor to be interacted by A M 
[16,17]. 
2. Materials and methods 
2.1. Materials 
Human AM, human PAMP, and CGRPs_37 was purchased from 
the Peptide Institute, Inc. (Osaka, Japan). PTX was purchased from 
Seikagaku, Co. (Tokyo, Japan), MTT (3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide) from Sigma Chemical Co. (St. 
Louis, MO, USA), AM22-52 from Phoenix Pharmaceuticals, Inc. 
(Mountain View, CA, USA), and co-conotoxin GIVA (co-CTX) from 
Biomol Research Laboratories, Inc. (Plymouth Meeting, PA, USA). 
2.2. Cell culture 
Human neuroblastoma TGW cells [15] were cultured in RPMI me-
dium supplemented with 10% fetal bovine serum (FBS). For MTT or 
BrdU5-bromo-2'-deoxyuridine) study, the cells were seeded into 96-
well polyvinylchloride plates at a density of approximately 105 cells/ 
mL (100 uL/well) in RPMI medium with 1.0% FBS. After 24 h in-
cubation, PAMP at dose of 10~7, 3 X 10~7, or 10~6 mol/L and AM at 
dose of 5Xl0~9 , 2x l0~ 8 , or 5XlO~8 mol/L were added into each 
well. Also, simultaneously administration of CGRPg_37 (10~5 mol/L 
for PAMP, 10"6 mol/L for AM), AM22-52 (10"
6 mol/L), PTX (1 mg/ 
mL), and co-CTX (10~7 mol/L) was done in some wells. 
2.3. Assay 
Cell growth was assayed by MTT method 24, 48, and 96 h after 
treatments. In brief, we added 10 u.L of MTT (5 mg/mL) into wells. 
After 4 h incubation, we removed medium and cells was solubilized by 
100 uL dimethylsulfoxide. The Bio-Rad microplate Manager plate 
reader (Model 3550) and software was used to determine the number 
of viable cells measured with excitation 570 nm and remission 630 nm. 
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DNA synthesis was examined by BrdU incorporation assay kit (Cell 
Proliferation ELISA System, version 2; Amersham International pic, 
Buckinghamshire, UK) 96 h after treatments. 
2.4. Statistical analysis 
Each experiment was done with triplet and repeated 3 to 4 times. 
The average of these data are expressed as mean ± S.E.M. The data of 
MTT assay and BrdU incorporation was expressed as percentage of 
the data with control (untreated) cells. They were evaluated by one-
way or two-way analysis of variance (ANOVA) and subsequent multi-
ple comparison by Tukey's method. P-values of < 0.05 level were 
accepted as significant. 
3. Results 
Both PAMP (10 - 6 mol/L) and AM (5X 10"8 mol/L) inhib-
ited cell growth as shown in Fig. 1: the significant inhibition 
was observed 48 h after treatment (PAMP: 72±11%, AM: 
88 ± 3%, P < 0.05, respectively) and this effect was continued 
to at least 96 h (PAMP: 56±16%, AM: 70±5%, P<0.05). 
The inhibitory effect of 96 h treatment of PAMP and AM on 
growth of TGW cells was dose-dependent fashion (Fig. 2). 
Simultaneous administration of 10 - 5 mol/L of CGRP8_37 
did not affect the suppression of PAMP (5X 10~8 mol/L) on 
cell growth (81 ± 7% vs. 55 ± 3%, P < 0.05) but 1 mg/mL PTX 
abolished it (60 ± 2% vs. 63 ± 1%, n.s.; Fig. 3). Also, the effect 
of PAMP was inhibited by 10"7 mol/L co-CTX (72 ±7% vs. 
87 ± 12%, n.s.). In contrast, the effect of AM (10~6 mol/L) was 
blocked by CGRP8_37 (88 ±7% vs. 89 ±5%, n.s.) and 
AM22-52 (105 ±7% vs. 108 ±6%, n.s.) but not by PTX 
(69 ±4% vs. 52 ±2%, i><0.05). The results of the BrdU in-
corporation showed similar tendency (Fig. 4). Both PAMP 
and AM inhibited growth of neuroblastoma cells (PAMP: 
29±19%, AM: 79±4%, i><0.05, respectively). The PAMP-
induced suppression of DNA synthesis was abolished by PTX 
alone (23 ±11% vs. 23 ±5%, P<0.05) whereas the effect of 
AM was blocked by CGRP8 37 (88 ±17% vs. 92 ±7%, 
P<0.05) . 
4. Discussion 
We firstly demonstrated the effect of PAMP on cell growth: 
The proliferation of human neuroblastoma TGW cells was 
attenuated by PAMP as well as AM. However, PAMP inhib-
ited cell growth at higher (about 20-50 times) doses than AM 
did: Similarly, hypotensive effect of AM is greater (about 50 
times) than that of PAMP in conscious rats in our previous 
study [6]. The mechanism of the effects should be different 
between PAMP and AM. The inhibition of cell growth by 
PAMP was abolished by PTX and co-CTX whereas that by 
AM was blocked by CGRP8_37 and AM22_52. Thus, PAMP 
attenuates the growth of neuroblastoma cells possibly by in-
hibiting N-type Ca2+ channels through PTX-sensitive G pro-
tein-coupled receptors but AM does not. In contrast to AM, 
cyclic AMP formation is not affected by rat PAMP in rat 
VSMC, which reveals PAMP binding sites [12]. 
We have already demonstrated that PAMP exhibits vaso-
dilator effect through the peripheral sympathetic suppression, 
which is due to blockade of norepinephrine release [5,6]. The 
previous report suggests that PAMP inhibits the N-type Ca2+ 
channel through PTX-sensitive G protein in nerve growth 
factor-treated PC 12 cells [10]. In the present study, PTX 
and co-CTX abolished the effect of PAMP on growth of neu-
roblastoma cells. Thus, changes in intracellular Ca2+ might be 
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Fig. 1. Time-dependent effect of proadrenomedullin N-terminal 20 
peptide (PAMP: 10~6 mol/L; open circle) and adrenomedullin 
(AM: 5X10"8 mol/L; closed circle) on growth of TGW cells. 
*P<0.05. 
intimately related to the cell growth inhibition because N-type 
Ca2+ channel has been demonstrated to be coupled to PTX-
sensitive G protein in neuroblastoma cells [18,19]. In fact, 
Ca2+ channel antagonists, such as verapamil, nifedipine, dil-
tiazem, Ni2+ , and Co2 + , inhibit growth of human neuroblas-
toma cells probably through interference with agonist-induced 
intracellular Ca2+ mobilization [20]. Also, K+ channel modu-
lators and high extracellular K+ inhibit cell growth accompa-
nied with blockade of intracellular Ca2+ mobilization in neu-
roblastoma cells [21]. Although we did not observed 
morphological changes in TGW cells, blockade of intracellu-
lar Ca2+ mobilization by TMB-8 (8-[./V,./V-dimethlyamino)oc-
tyl-3,4,5-trimethoxybenzoate hydrochloride) induces neuro-
blastoma cell differentiation [22]: PAMP might induce cell 
differentiation in the other experimental condition. Moreover, 
because PAMP receptors are widely distributed [12], PAMP 
may also exert antiproliferative effect in other cells than neu-
ral cells. 
The inhibition of growth of neuroblastoma cells with AM 
was reversed by CGRP8_37 and AM22_52, which is similar to 
the results in cultured rat mesangial cells [23]: both CGRP8_37 
and AM22_52 inhibited the increased production of cyclic 
AMP by AM or CGRP. Thus, CGRP-related receptor may 
play an important role. However, CGRP8_37 slightly inhibited 
the cell growth (control of PAMP: 81 ± 7%, P< 0.05, control 
of AM: 88±7%, n.s.) but AM22_52 did not affect it at all 
(105 ± 7%, n.s.). This might be due to intrinsic factors affected 
CGRP receptors other than AM, such as CGRP or amylin 
[24], which might stimulate growth of neuroblastoma cells. 
Although AM22_52 antagonizes vasodilator response to 
CGRP but not AM in the cat [25], AM22_52 might block 
the other receptors than CGRP receptors, resulting in un-
changed cell growth. However, the present data did not clarify 
the different response of TGW cells between CGRP8_37 and 
AM22_52, so the further investigation should be required. 
Thus, multiple receptors might affect growth of neuroblasto-
ma cells although the cells have a receptor to be interacted by 
both AM and CGRP [16,17]. AM has been reported to mod-
ify cell growth by several investigators, which is different be-
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Fig. 2. Effect of proadrenomeduUin N-terminal 20 peptide (PAMP; closed column) and adrenomedullin (AM; shaded column) at different dose 
on growth of TGW cells. *P<0.05. 
tween cell types: AM suppresses the growth in rat mesangial 
cells and VSMC [13] but stimulates it in Swiss 3T3 cells [14]. 
Also, MoAb-G6 (polyclonal antibody against P072, a frag-
ment of AM) has been demonstrated to inhibit growth of 
several human tumor cell lines [26]. On the other hand, in 
hepatic pericytes, AM has negligible effects on DNA and pro-
tein synthesis [27]. These phenomena accompany with the 
elevation of cyclic AMP (even in hepatic pericytes) so these 
results suggest that the responses to cyclic AMP are different 
between cell types. In cultured human neuroblastoma cell 
lines, the increased generation of cyclic AMP by vasoactive 
intestinal peptide [28,29], pituitary adenylate cyclase activating 
peptide-38 [29], and Eudistoma alkaloids [30] induces the 
growth inhibition. Thus, increased cyclic AMP with AM 
treatment may also inhibit growth of the neuroblastoma cells. 
Recently, AM has been demonstrated in neural cells in mouse 
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Fig. 3. Influence of calcitonin gene-related peptide (CGRP)8-37 and pertussis toxin (PTX) on the effect of proadrenomeduUin N-terminal 20 
peptide (PAMP; closed column) and adrenomedullin (AM; shaded column) on growth of TGW cells. *P<0.05. 
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and rat embryo, suggesting that A M plays a role in differ-
entiation of neural tissues [31]. 
In conclusion, P A M P inhibits the neuroblastoma cell 
growth through PTX-sensitive G protein-coupled receptors 
whereas A M induces the inhibition of cell growth through 
the other mechanism(s). Both peptides may contribute to 
the regulation of neural cell growth and differentiation 
through different ways. 
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